The training, developed by the MAPS, aims to “enhance the knowledge, attitudes, and skills of first responders to quickly recognize and effectively respond to emotional and behavioral crisis incidents involving psilocybin and other psychedelics.”

Psychedelic medicine investigators must contend with strict guidelines and administrative burdens, which can slow research efforts and subsequent approvals that could improve wide-spread access and economic opportunities.

In the absence of tailored treatment options, perhaps it’s no surprise that a growing interest in Psychedelic-Assisted Therapy (PAT) for eating disorders is slowly gaining traction.

MindMed, the first publicly traded pharmaceutical company focused on psychedelics, said its drug has received a breakthrough designation from the FDA.

At a hearing Tuesday, members of the House Military and Veterans Affairs Committee agreed to advance the measure with individual recommendations.

Cleveland Clinic is now part of a multisite trial with over 50 sites researching this drug to treat treatment-resistant depression.

New research is stirring interest in ibogaine, which appears to help ease the agony of detox and prevent relapse. Used in other countries, it remains illegal in the U.S.

As early as this spring, the federal government could allow members of a Spokane religious congregation to lay on the grassy floor of a nondescript building to consume their sacrament – ayahuasca.

The bill creates a highly-controlled pilot project involving Intermountain Healthcare and University of Utah Health, where patients could try such drugs.

An earlier version of Connecticut’s psilocybin decriminalization bill passed the House last year but did not advance in the Senate.

Results for the small study were positive, but the bipolar population is at a higher risk of mania from psychedelic treatments.

If passed, the legislation would legalize the supervised therapeutic use of psilocybin for adults.

Central to Odyssey’s mission are 4-day group retreats and private sessions tailored for individuals seeking personal and mental health breakthroughs.

The study was the first randomized clinical trial to include those with bipolar II disorder (BDII) and the first to adopt a flexible repeat dosing regime, among other things.

This comes months after FDA issued historic draft guidance on psychedelics studies, providing scientists with a framework to carry out research that could lead to the development of novel medicines.

The measure would allow the Department of Human Services (DHS) to license psilocybin-assisted therapy centers in the state, where trained facilitators could administer the psychedelic.

The agency will decide in August whether MDMA-assisted therapy can be prescribed by doctors.

After a failed attempt to decriminalize a short list of psychedelics last year, state Sen. Scott Wiener (D-San Francisco) is reintroducing legislation to make California the third state to legalize psychedelic-assisted therapy for adults.

If it becomes law, the measure would create a therapeutic psilocybin research fund “for the purpose of providing financial assistance to research institutions in Indiana to study…the use of psilocybin to treat mental health and other medical conditions.”

Josh Hardman, founder and editor of Psychedelic Alpha, interviews the journalist about his forthcoming book, and how it “marries the tracing of complex lineages that inform today’s so-called psychedelic renaissance with his own endeavour to better understand both his personal and family histories and present realities.”